Feb 17, 2026 7:45 am EST TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
Feb 12, 2026 7:45 am EST TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 2, 2026 7:45 am EST TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
Dec 15, 2025 7:50 am EST TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
Dec 8, 2025 7:50 am EST TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
Nov 14, 2025 7:00 am EST TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nov 3, 2025 9:01 am EST TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
Aug 20, 2025 8:00 am EDT TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference